Skip to main content
. 2009 Aug 18;100(12):2402–2410. doi: 10.1111/j.1349-7006.2009.01315.x

Figure 2.

Figure 2

 IC50 of 5‐fluorouracil (5FU) in combination with mammalian target of rapamycin (mTOR) inhibitor. The IC50 of 5FU was decreased when combined with rapamycin or CCI‐779 in OCUM‐2M (a) and OCUM‐8 (b) scirrhous gastric cancer cells. In contrast, the IC50 of 5FU was increased when combined with rapamycin or CCI‐779 in MKN‐45 (c) and MKN‐74 (d) non‐scirrhous gastric cancer cells.